Pfizer gets obesity drug approval in China shortly after buying local rights
辉瑞在收购本土权益后不久获manbetx3.0 批准其减重药物

Pfizer was a late arrival to the obesity gold rush, but it just hit its first seam.
辉瑞虽迟入肥胖治疗这场淘金热，但刚刚挖到第一条富矿。

发布于2026年3月6日 Elizabeth Cairns

本报道最初发表于Endpoints News。请点击这里查看原文

Pfizer was a late arrival to the obesity gold rush, but it just hit its first seam.

在这场减肥药物的淘金热中，辉瑞(Pfizer)起步较晚，但它刚刚挖到了第一条富矿脉。

您已阅读4%（157字），剩余96%（3815字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。

Pfizer gets obesity drug approval in China shortly after buying local rights辉瑞在收购本土权益后不久获manbetx3.0 批准其减重药物